Clinical trial · Interventional
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study
NCT01484015CI-TRIAL-00033847completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized pilot clinical trial studies how well giving prolonged infusion compared to standard infusion of cefepime hydrochloride works in treating patients with febrile neutropenia. Giving cefepime hydrochloride over a longer period of time may be more effective than giving cefepime hydrochloride over the standard time.
Conditions
Conditions (39)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | Adult Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia | ONTOLOGY_EXACT | 0.98 |
| Adult Burkitt Lymphoma | Adult Burkitt Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Adult Diffuse Large Cell Lymphoma | — | UNRESOLVED | — |
| Adult Diffuse Mixed Cell Lymphoma | — | UNRESOLVED | — |
| Adult Diffuse Small Cleaved Cell Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.85 |
| Adult Hodgkin Lymphoma | Adult Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Adult Immunoblastic Large Cell Lymphoma | Adult Immunoblastic Lymphoma | ALIAS | 0.90 |
| Adult Lymphoblastic Lymphoma | Adult Lymphoblastic Lymphoma |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cefepime hydrochloride | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm I (standard infusion)
- description
- Patients receive cefepime hydrochloride IV over 30 minutes.
- interventionNames
- Drug: cefepime hydrochloride
- type
- EXPERIMENTAL
- label
- Arm II (prolonged infusion)
- description
- Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
- interventionNames
- Drug: cefepime hydrochloride
Primary outcomes (1)
- measure
- Defervescence (without hypothermia)
- timeFrame
- 72 hours
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Absolute neutrophil count \< 500 cells/mm\^3 or \< 1000 cells/mm\^3 with a predicted decrease to \< 500 cells/mm\^3 * Temperature \> 38.0 degrees Celsius * Received chemotherapy or stem-cell transplant as treatment for malignancy or myelodysplastic syndrome (MDS) * Cefepime prescribed at a dose of 2 grams IV every 8 hours Exclusion Criteria: * Allergy to a cephalosporin antibiotic * Estimated creatinine clearance \< 50 milliliters/minute * Concurrent anti-gram negative antimicrobials * Diagnostic criteria suggestive of sepsis * Circumstances which may make 3 hour infusion impractical * Solid tumor malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.